

following anti-core monoclonal antibodies may also be utilized for purposes of the present invention: 107-35-54, 110-81-17, 13-975-157, 14-1350-210 (see U.S. Patent No. 5,753,430) and Tonen HCV core monoclonals C11-3, 7, 10, 14 and 15 (see PCT Application WO 099/06836), all of which are available from the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209. (For a discussion of the manner in which monoclonal antibodies may be created, see Kohler and Milstein, *Nature* (1975) 256:494, and reviewed in *Monoclonal Hybridoma Antibodies: Techniques and Applications*, ed. Hurrell (CRC Press, Inc., 1982); see also J.W. Goding in *Monoclonal Antibodies: Principles and Practice* (Academic Press, N.Y., 1983; see also U.S. Patent No. 5,753,430).

B1
condit.
Ex. note → Page ¹⁹ ~~18~~, line 15 - line 36, please replace Table I with the following:

TABLE I
HCV-Core Derived Peptides

<u>Peptide</u>	<u>Sequence</u>	<u>Core Reg. Repr.</u>
A	MSTNPKPQKKNKRNTNRR	(SEQ ID NO:46) 1-18
B	NKRNTNRRPQDVKFPGGG	(SEQ ID NO:47) 11-28
C	DVKFPGGGQIVGGVYLLP	(SEQ ID NO:48) 21-38
D	VGGVYLLPRRGPRLGVRA	(SEQ ID NO:49) 31-48
E	GPRLGVRATRKTSERSQP	(SEQ ID NO:50) 41-58
F	KTSERSQPRGRRQPIPKA	(SEQ ID NO:51) 51-68
G	RRQPIPKARRPEGRTWAQ	(SEQ ID NO:52) 61-78
H	PEGRTWAQPGYPWPLYGN	(SEQ ID NO:53) 71-88
I	QYPWPLYGNEGCGWAGWLL	(SEQ ID NO:54) 81-98
J	CGWAGWLLSPRGSRPSW	(SEQ ID NO:55) 91-107
1	WLLSPRGSRPSWGPTDPRRSRN LG	(SEQ ID NO:56) 96-120
2	SWGPTDPRRRSRNLGKVIDTLTCGF	(SEQ ID NO:57) 106-130
3	SRNLGKVIDTLTCGFADLMGYIPLV	(SEQ ID NO:58) 116-140
4	LTCGFADLMGYIPLVGAPLGGAA RA	(SEQ ID NO:59) 126-150
5	YIPLVGAPLGGAAARALAHGVRVLED	(SEQ ID NO:60) 136-160
6	GAARALAHGVRVLEDGVNYATGNLP	(SEQ ID NO:61) 146-170
7	LEDGVNYATGNLPGCSFSIFLLA	(SEQ ID NO:62) 158-180
8	LPGCSFSIFLLALLSCLTVPASA	(SEQ ID NO:63) 169-191